Initial clinical studies investigating the effects of BMP-2 administered via an ACS, including the large, multi-centered human “BMP-2 evaluation in surgery for tibial trauma” study (BESTT), showed superior effects of the treatment due to decreased rates of revision surgeries and infections with a 1.5 mg/mL BMP-2 dosage [20]. This evidence concerns the gene BMP2 and infection.